J. Goldman & CO LP Black Diamond Therapeutics, Inc. Transaction History
J. Goldman & CO LP
- $3.8 Billion
- Q1 2025
A detailed history of J. Goldman & CO LP transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 256,499 shares of BDTX stock, worth $556,602. This represents 0.01% of its overall portfolio holdings.
Number of Shares
256,499Holding current value
$556,602% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding BDTX
# of Institutions
94Shares Held
41.1MCall Options Held
45.1KPut Options Held
37K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.4MShares$22.6 Million0.01% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$12.2 Million0.62% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$9.65 Million0.65% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$6.98 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.73MShares$5.93 Million0.1% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $78.9M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...